Medicines Development Retains the Services of d3 Medicine

November 25, 2015

Medicines Development for Global Health has retained the services of d3 Medicine to provide strategic advice on the regulatory strategy to support the registration of moxidectin for onchocerciasis. The services of d3 Medicine have been retained through an innovative risk-share agreement for the benefit of both companies.

Read press release.